INNATE PHARMA SA (IPHYF:OTCMKTS)
$0 None (None%)
Analysed INNATE PHARMA SA (IPHYF:OTCMKTS) News Sources
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
23-07-2026
yahoo.com
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
10-08-2026
yahoo.com
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
10-08-2026
yahoo.com
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
10-08-2026
yahoo.com
Sobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III
10-08-2026
pharmaceutical-technology.com
Innate Pharma Announces Conference Call and Webcast
14-08-2026
yahoo.com
Innate Pharma Secures €30M, Extends Cash Runway Into 2028
14-08-2026
marketbeat.com
Swedish Orphan Biovitrum (OM:SOBI) Following Its Lacutamab Deal And The Undervalued Narrative
15-08-2026
yahoo.com
Innate Pharma SA (IPHA) (Q2 2026) Earnings Call Highlights: Strategic Partnerships and Pipeline ...
17-08-2026
yahoo.com
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
02-09-2026
yahoo.com
What is the current price of INNATE PHARMA SA (IPHYF:OTCMKTS)?
The current price of INNATE PHARMA SA (IPHYF:OTCMKTS) is $0.
INNATE PHARMA SA (IPHYF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of INNATE PHARMA SA (IPHYF:OTCMKTS) since the previous trading day is $None.
INNATE PHARMA SA (IPHYF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of INNATE PHARMA SA (IPHYF:OTCMKTS) since the previous trading day is None%.
What is the most recent average sentiment score for INNATE PHARMA SA (IPHYF:OTCMKTS)?
The most recent average sentiment score for INNATE PHARMA SA (IPHYF:OTCMKTS) is 71 out of 100.
What is the most recent average sentiment for INNATE PHARMA SA (IPHYF:OTCMKTS)?
The most recent sentiment for INNATE PHARMA SA (IPHYF:OTCMKTS) is .
SEC-8K** Filing Available For INNATE PHARMA SA (IPHYF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.